Abstract
Palbociclib (PAL), in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy (ET) or with fulvestrant (FUL), is indicated for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) ABC/mBC. This analysis describes real-world patient (pt) characteristics, treatment patterns, and preliminary tumour response in pre/perimenopausal women with HR+/HER2– ABC/mBC enrolled in the POLARIS study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
